{"id":295,"date":"2023-04-26T11:34:41","date_gmt":"2023-04-26T11:34:41","guid":{"rendered":"https:\/\/kinasconsulting.org\/?page_id=295"},"modified":"2023-05-19T06:39:20","modified_gmt":"2023-05-19T06:39:20","slug":"therapy","status":"publish","type":"page","link":"https:\/\/kinasconsulting.org\/pl\/terapia-2\/","title":{"rendered":"Terapia"},"content":{"rendered":"\n
\n
\n <\/span><\/span><\/span>
\n
\n \n
\n

\n \n Kompleksowa kombinacja <\/span>\n\n \n \n <\/span>\n <\/h2>\n<\/div>\n\n\n
\n
\n

Nasza spersonalizowana immunoterapia jest ukierunkowana na guz bez niszczenia zdrowych\nkom\u00f3rek. Osi\u0105gamy to poprzez \u0142\u0105czenie r\u00f3\u017cnych metod leczenia.<\/span><\/p>\n

\u00a0<\/h3> <\/div>\n<\/div>\n <\/div>\n
\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n
\n
\n \n
\n

\n \n Szczepionka dendrytyczna <\/span>\n\n \n \n <\/span>\n <\/h2>\n<\/div>\n\n\n
\n
\n

Podstaw\u0105 i najwa\u017cniejszym elementem naszej Immunoterapii jest opracowana przez nasze\nlaboratorium szczepionka indywidualnie przygotowywana dla ka\u017cdego pacjenta. M\u00f3wi\u0105c\npro\u015bciej, \u0142\u0105czymy wirusa onkolitycznego i materia\u0142 guza pacjenta z kom\u00f3rkami\ndendrytycznymi w naszym laboratorium, aby wyprodukowa\u0107 spersonalizowan\u0105 szczepionk\u0119.\nTa szczepionka nast\u0119pnie aktywuje uk\u0142ad odporno\u015bciowy pacjenta do walki z guzem. Nasza\nklinika jest jedyn\u0105 instytucj\u0105 w Europie, kt\u00f3ra uzyska\u0142a zgod\u0119 organ\u00f3w regulacyjnych na\nprodukcj\u0119 takiej szczepionki.<\/span><\/p> <\/div>\n<\/div>\n <\/div>\n

\n \n
\n
\n \"7\" \n <\/div>\n \n \n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n <\/span><\/span><\/span>
\n
\n <\/div>\n
\n
\n
\n \n
\n

\n \n Wiroterapia <\/span>\n\n \n \n <\/span>\n <\/h2>\n<\/div>\n\n\n
\n
\n

Wiroterapia jest integraln\u0105 cz\u0119\u015bci\u0105 naszej immunoterapii. Wirusy onkolityczne, takie jak\nwirus choroby Newcastle (NDV), to wirusy, kt\u00f3re atakuj\u0105 kom\u00f3rki nowotworowe natomiast\ns\u0105 nieszkodliwe dla kom\u00f3rek zdrowych. Kiedy wirus replikuje si\u0119 w kom\u00f3rkach\nnowotworowych, uk\u0142ad odporno\u015bciowy jest ostrzegany i zauwa\u017ca kom\u00f3rki nowotworowe. W\nwyniku infekcji wirusowej kom\u00f3rki nowotworowe zostaj\u0105 sklasyfikowane jako niebezpieczne\ni s\u0105 aatakowane.<\/span><\/p> <\/div>\n<\/div>\n\n

\n
\n \"9\" \n <\/div>\n \n \n <\/div>\n\n
\n

\n \n Hipertermia <\/span>\n\n \n \n <\/span>\n <\/h2>\n<\/div>\n\n\n
\n
\n

Modulowana elektrohipertermia powoduje podwy\u017cszenie temperatury i stymulacj\u0119 kom\u00f3rek\nnowotworowych poprzez fale elektromagnetyczne, bez wp\u0142ywu na zdrow\u0105 tkank\u0119. W ten spos\u00f3b kom\u00f3rki nowotworowe wytwarzaj\u0105 na swojej powierzchni pewne sygna\u0142y ostrzegawcze, kt\u00f3re prowokuj\u0105 i intensyfikuj\u0105 reakcj\u0119 immunologiczn\u0105. W umiarkowanej hipertermii ca\u0142ego cia\u0142a pod wp\u0142ywem \u015bwiat\u0142a podczerwonego generowany jest podobny do gor\u0105czki wzrost temperatury cia\u0142a. To pasywne podwy\u017cszenie temperatury stymuluje kom\u00f3rki odporno\u015bciowe odpowiedzialne za zwalczanie guza.<\/span><\/p> <\/div>\n<\/div>\n <\/div>\n

\n \n
\n

\n \n Terapia inhibitorami punkt\u00f3w kontrolnych <\/span>\n\n \n \n <\/span>\n <\/h2>\n<\/div>\n\n\n
\n
\n

Punkty kontrolne to mechanizmy, za pomoc\u0105 kt\u00f3rych uk\u0142ad odporno\u015bciowy jest regulowany\nprzed nadmiern\u0105 aktywacj\u0105. Nowotwory \u201eniew\u0142a\u015bciwie wykorzystuj\u0105\u201d kontrole\nimmunologiczne, znane r\u00f3wnie\u017c jako punkty kontrolne, do dezaktywacji skierowanej\nprzeciwko nim odpowiedzi immunologicznej. Tutaj do gry wchodz\u0105 inhibitory punkt\u00f3w\nkontrolnych: hamuj\u0105 zablokowane szlaki sygna\u0142owe. W pewnym sensie zwalniaj\u0105 one\nhamulce kom\u00f3rek odporno\u015bciowych i w ten spos\u00f3b umo\u017cliwiaj\u0105 uk\u0142adowi odporno\u015bciowemu\nponown\u0105 walk\u0119 z nowotworem. Inhibitory punktu kontrolnego PD-1 s\u0105 jednak skuteczne\ntylko wtedy, gdy odpowied\u017a immunologiczna przeciwko nowotworowi ju\u017c istnieje.<\/span><\/p> <\/div>\n<\/div>\n\n

\n

\n \n Modulacja mikro\u015brodowiska guza <\/span>\n\n \n \n <\/span>\n <\/h2>\n<\/div>\n\n\n
\n
\n

Mikro\u015brodowisko guza odnosi si\u0119 do struktury tkanki \u0142\u0105cznej, w kt\u00f3rej osadzony jest guz.\nIstnieje bezpo\u015brednia interakcja mi\u0119dzy t\u0105 tkank\u0105 a kom\u00f3rkami nowotworowymi, co ma\nwp\u0142yw na wzrost kom\u00f3rek nowotworowych i skuteczno\u015b\u0107 immunoterapii. St\u0105d nasza\nimmunoterapia uwzgl\u0119dnia i moduluje mikro\u015brodowisko guza.<\/span><\/p> <\/div>\n<\/div>\n\n

\n

\n \n Optymalizacja mikroelement\u00f3w i witamin <\/span>\n\n \n \n <\/span>\n <\/h2>\n<\/div>\n\n\n
\n
\n

Aby uk\u0142ad odporno\u015bciowy funkcjonowa\u0142 optymalnie, musi by\u0107 zaopatrzony w odpowiedni\u0105 ilo\u015b\u0107 mikroelement\u00f3w i witamin. W razie potrzeby podajemy je specjalnie w celu\noptymalizacji odpowiedzi immunologicznej.<\/span><\/p> <\/div>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n

\n <\/div>\n <\/div>\n <\/div>\n
\n <\/span><\/span>
\n
\n
\n
\n <\/div>\n
\n <\/div>\n
\n <\/div>\n <\/div>\n
\n
\n \n
\n

\n \n Szczepionka dendrytyczna <\/span>\n\n \n \n <\/span>\n <\/h2>\n<\/div>\n\n\n
\n
\n

Demaskowanie kom\u00f3rek rakowych i skuteczna walka z nimi<\/span><\/h3>\n

Poprzez powtarzane stosowanie naszej szczepionki uk\u0142ad odporno\u015bciowy pacjenta jest\naktywowany i umo\u017cliwia wykrywanie mechanizm\u00f3w kamufla\u017cu kom\u00f3rek nowotworowych oraz podejmowanie dzia\u0142a\u0144 przeciwko nim. Kluczow\u0105 rol\u0119 odgrywaj\u0105 tu kom\u00f3rki dendrytyczne pe\u0142ni\u0105ce rol\u0119 przeka\u017anik\u00f3w oraz wirus, kt\u00f3ry nie jest szkodliwy dla cz\u0142owieka.\nPodobnie jak w przypadku zwyk\u0142ych szczepionek, uk\u0142ad odporno\u015bciowy mo\u017ce zbudowa\u0107 pami\u0119\u0107 immunologiczn\u0105 przeciwko antygenom nowotworowym, dzi\u0119ki czemu zapewniona jest d\u0142ugoterminowa skuteczno\u015b\u0107.<\/span><\/p> <\/div>\n<\/div>\n <\/div>\n

\n \n
\n
\n \"2\" \n <\/div>\n \n \n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n \n
\n
\n <\/div>\n<\/div>\n <\/div>\n
\n \n
\n

\n \n Sk\u0142adniki spersonalizowanej szczepionki <\/span>\n\n \n \n <\/span>\n <\/h2>\n<\/div>\n\n\n
\n
\n

U\u017cywanie wirus\u00f3w przeciwko nowotworowi
Niekt\u00f3re wirusy onkolityczne mog\u0105 namna\u017ca\u0107 si\u0119 tylko w kom\u00f3rkach nowotworowych,\nniszcz\u0105c je przy okazji, podczas gdy zdrowe kom\u00f3rki mog\u0105 broni\u0107 si\u0119 przed wirusem. Wirus\nchoroby Newcastle (NDV) jest takim wirusem. Jest ca\u0142kowicie nieszkodliwy dla ludzi:\nnamna\u017ca si\u0119 wy\u0142\u0105cznie w ludzkich kom\u00f3rkach nowotworowych, nie uszkadzaj\u0105c zdrowych\nkom\u00f3rek. Zainfekowane kom\u00f3rki nowotworowe wysy\u0142aj\u0105 sygna\u0142y ostrzegawcze, kt\u00f3re\nalarmuj\u0105 i aktywuj\u0105 uk\u0142ad odporno\u015bciowy. W ten spos\u00f3b wirus Newcastle zwi\u0119ksza\nefektywno\u015b\u0107 naszej szczepionki.<\/p> <\/div>\n<\/div>\n\n

\n
\n <\/div>\n<\/div>\n <\/div>\n
\n <\/div>\n <\/div>\n <\/div>\n
\n <\/span><\/span><\/span>
\n
\n
\n
\n \n
\n
\n \"31\" \n <\/div>\n \n \n <\/div>\n <\/div>\n
\n \n
\n

\n \n Produkcja szczepionki <\/span>\n\n \n \n <\/span>\n <\/h2>\n<\/div>\n\n\n
\n
\n

Pierwszym krokiem jest pobranie pr\u00f3bki krwi od pacjenta. W naszym laboratorium\nizolowane s\u0105 i hodowane na kom\u00f3rki dendrytyczne monocyty, rodzaj krwinek bia\u0142ych. S\u0105 one\ndojrzewane w laboratorium i zawieraj\u0105 informacje o sk\u0142adnikach guza i sygna\u0142ach zagro\u017cenia wirusowego. Po szczepieniu kom\u00f3rki dendrytyczne prezentuj\u0105 cz\u0105steczki specyficzne dla nowotworu uk\u0142adowi odporno\u015bciowemu pacjenta i w ten spos\u00f3b aktywuj\u0105 limfocyty T. Rol\u0105 limfocyt\u00f3w T jest niszczenie chorych kom\u00f3rek. Dzi\u0119ki informacjom, kt\u00f3re otrzyma\u0142y kom\u00f3rki T mog\u0105 one teraz rozpoznawa\u0107 i atakowa\u0107 kom\u00f3rki nowotworowe w ca\u0142ym ciele.<\/span><\/p>\n

Zasada szczepienia kom\u00f3rkami dendrytycznymi, na kt\u00f3rej opiera si\u0119 nasza szczepionka, od\nkilku lat jest przedmiotem intensywnych bada\u0144. Pierwszym zatwierdzonym lekiem tego typu\njest Provenge (Sipuleucel T) przeciw rakowi prostaty. To jednak nie wykorzystuje w\u0142asnego\nmateria\u0142u nowotworowego pacjenta, ale wykorzystuje wst\u0119pnie wybrane antygeny. Na\nzaawansowanym etapie bada\u0144 klinicznych kolejna szczepionka (DC-Vax) wykaza\u0142a obiecuj\u0105ce wyniki, ale nie zosta\u0142a jeszcze zatwierdzona. Ta szczepionka wykorzystuje r\u00f3wnie\u017c kom\u00f3rki dendrytyczne za\u0142adowane lizatem nowotworu od pacjenta. Nie zawiera jednak wirusa onkolitycznego, aby zwi\u0119kszy\u0107 jej skuteczno\u015b\u0107.<\/span><\/p> <\/div>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n","protected":false},"excerpt":{"rendered":"

Nasza spersonalizowana immunoterapia jest ukierunkowana na guz bez niszczenia zdrowych\nkom\u00f3rek. Osi\u0105gamy to poprzez \u0142\u0105czenie r\u00f3\u017cnych metod leczenia. \u00a0<\/p>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-295","page","type-page","status-publish","hentry","has-post-title","has-post-date","has-post-category","has-post-tag","has-post-comment","has-post-author",""],"builder_content":"

Comprehensive combination<\/h2>\n

Our personalized immunotherapy targets the tumor without destroying healthy cells. We achieve this by combining different treatments.<\/p>

\u00a0<\/h3>\n

Dendritic vaccine<\/h2>\n

The basis and the most important element of our Immunotherapy is a vaccine developed by our laboratory, individually prepared for each patient. Put simply, we combine the oncolytic virus and the patient's tumor material with the dendritic cells in our laboratory to produce a personalized vaccine. This vaccine then activates the patient's immune system to fight the tumor. Our clinic is the only institution in Europe that has obtained regulatory approval for the production of such a vaccine.<\/p>\n\"7\"\n

Virotherapy<\/h2>\n

Virotherapy is an integral part of our immunotherapy. Oncolytic viruses, such as Newcastle disease virus (NDV), are viruses that attack cancer cells but are harmless to healthy cells. When the virus replicates in the cancer cells, the immune system is alerted and notices the cancer cells. As a result of viral infection, cancer cells are classified as dangerous and are attacked.<\/p>\n\"9\"\n

Hyperthermia<\/h2>\n

Modulated electrohyperthermia causes an increase in temperature and stimulation of cancer cells through electromagnetic waves, without affecting healthy tissue. In this way, cancer cells produce certain warning signals on their surface that provoke and intensify the immune reaction. In moderate whole-body hyperthermia, a fever-like increase in body temperature is generated under the influence of infrared light. This passive increase in temperature stimulates the immune cells responsible for fighting the tumor.<\/p>\n

Therapy with checkpoint inhibitors<\/h2>\n

Checkpoints are the mechanisms by which the immune system is regulated from over-activation. Cancers \"misuse\" immune checks, also known as checkpoints, to deactivate the immune response directed against them. This is where checkpoint inhibitors come into play: they inhibit blocked signaling pathways. In a sense, they release the brakes on the immune cells and thus allow the immune system to fight the tumor again. However, PD-1 checkpoint inhibitors are only effective when an immune response against the tumor is already in place.<\/p>\n

Tumor microenvironment modulation<\/h2>\n

The tumor microenvironment refers to the connective tissue structure in which the tumor is embedded. There is a direct interaction between this tissue and cancer cells, which affects the growth of cancer cells and the effectiveness of immunotherapy. Hence, our immunotherapy takes into account and modulates the tumor microenvironment.<\/p>\n

Optimization of micronutrients and vitamins<\/h2>\n

For the immune system to function optimally, it must be supplied with the right amount of microelements and vitamins. We give them specifically to optimize the immune response when needed.<\/p>\n

Dendritic vaccine<\/h2>\n

Unmasking cancer cells and effectively fighting them<\/h3>

Through the repeated use of our vaccine, the patient's immune system is activated and allows the camouflage mechanisms of the cancer cells to be detected and acted upon. The key role here is played by dendritic cells acting as messengers and a virus that is not harmful to humans. As with regular vaccines, the immune system can build an immune memory against tumor antigens, thus ensuring long-term effectiveness.<\/p>\n\"2\"\n\n

Components of a personalized vaccine<\/h2>\n

Using viruses against cancer
Some oncolytic viruses can multiply only in cancer cells, destroying them in the process, while healthy cells can defend themselves against the virus. Newcastle disease virus (NDV) is such a virus. It is completely harmless to humans: it multiplies only in human cancer cells, without damaging healthy cells. Infected cancer cells send out warning signals that alert and activate the immune system. In this way, Newcastle virus increases the effectiveness of our vaccine.<\/p>\n\n\"31\"\n

Vaccine production<\/h2>\n

The first step is to take a blood sample from the patient. In our laboratory, monocytes, a type of white blood cell, are isolated and grown into dendritic cells. They are matured in the lab and contain information about tumor components and viral threat signals. After vaccination, dendritic cells present tumor-specific molecules to the patient's immune system and thus activate T cells. The role of T cells is to destroy diseased cells. Thanks to the information the T cells have received, they can now recognize and attack cancer cells throughout the body.<\/p>

The principle of dendritic cell vaccination, on which our vaccine is based, has been the subject of intensive research for several years. The first approved drug of this type is Provenge (Sipuleucel T) against prostate cancer. This, however, does not use the patient's own tumor material, but uses pre-selected antigens. At an advanced stage of clinical trials, another vaccine (DC-Vax) has shown promising results but has not yet been approved. This vaccine also uses dendritic cells loaded with tumor lysate from the patient. However, it does not contain an oncolytic virus to increase its effectiveness.<\/p>","_links":{"self":[{"href":"https:\/\/kinasconsulting.org\/pl\/wp-json\/wp\/v2\/pages\/295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kinasconsulting.org\/pl\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/kinasconsulting.org\/pl\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/kinasconsulting.org\/pl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kinasconsulting.org\/pl\/wp-json\/wp\/v2\/comments?post=295"}],"version-history":[{"count":79,"href":"https:\/\/kinasconsulting.org\/pl\/wp-json\/wp\/v2\/pages\/295\/revisions"}],"predecessor-version":[{"id":603,"href":"https:\/\/kinasconsulting.org\/pl\/wp-json\/wp\/v2\/pages\/295\/revisions\/603"}],"wp:attachment":[{"href":"https:\/\/kinasconsulting.org\/pl\/wp-json\/wp\/v2\/media?parent=295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}